We deal with brands that provide high quality laboratory products to improve efficiency, performance and user experience. These products include purest plastic consumables that ensure the best results which were developed in response to customer needs.
Greiner Bio-One is an international medical technology company made up of four business divisions. Preanalytics develops innovative collection systems for human and veterinary samples that make the flow of daily routine tasks in hospitals, laboratories or doctors' surgeries simpler and safer. BioScience is technology partner to universities and research organizations, as well as to the diagnostics and pharmaceutical industries. BioScience is a leading supplier of specialist products for the analysis of cell cultures and microplates. Diagnostics specializes in the development of molecular-biological analysis methods. The field of DNA array applications ranges from human diagnostics to food technology. As an Original Equipment Manufacturer (OEM), Greiner Bio-One provides solutions in the area of custom-made design developments and production processes for the life sciences and medical sectors.
The innovative VACUETTE® blood collection tubes made from practically unbreakable plastic have become well established on the market. They have made the drawing of blood a safer and more hygienic process. The use of PET plastic offers the advantage that the tubes are as clear as glass.
In the healthcare sector sharps injuries account for most work-related transmissions of infectious diseases, whereby needlestick injuries present by far the greatest risk. More than 50% of all registered cases concern nursing staff, followed by doctors and laboratory staff.
Tubes are designed for routine use in immunohematology testing and viral marker testing in screening and clinical laboratories. The inner wall of each serum tube is coated with microscopic silica particles which activate the coagulation process when tubes are inverted. Tubes equipped with a gel separator contain a barrier gel in the base of the tube. During centrifugation, this gel forms a stable barrier between the serum and the blood cells, separating the serum from fibrin and cells.
Designed for use in the examination of coagulation parameters, coagulation tubes contain a buffered tri-sodium citrate solution. Citrate concentrations of either 3.2% (0.109M) or 3.8% (0.129M) are available, with a mixing ratio of one part citrate to nine parts blood.
As a potentially infectious sample material, urine must be transported, analysed and stored in a closed system. The sterile tubes and the matching accessories are particularly suited to microbiological and clinical chemistry diagnosis.
Blood collection accessories, as well as all other pointed and sharp objects, must be disposed of in non-penetrable containers. All sharps containers from Greiner Bio-One have a large opening for the disposal of sharp and pointed objects. The available volumes range from of 0.6 litres to up to 50 litres.
Oscar Medicare Pvt. Ltd. is New Delhi (India) based GMP and ISO: 13485 certified company engaged in R&D, manufacturing and marketing of in-vitro diagnostic kits in the range of Rapid tests, ELISA Kits, Serology Kits, Haematology Reagents, Biochemistry reagent kits etc. In the range of rapid tests, company is manufacturing and marketing tests for detection of HIV, HCV, HBs Ag, Syphilis, Typhoid, Malaria, Dengue, Troponin-I Pregnancy, Ovulation and Kala azar etc.
Oscar HIV-1& HIV-2 test is intended used for qualitative detection of antibodies (IgG/IgM/IgA) to HIV-1 and HIV-2 in human serum / plasma as in aid of HIV diagnosis. It is based upon lateral flow immuno assay and double antigen system has been used in the test formulation to have better sensitivity and specificity. Recombinant proteins GP-41 & GP-120 for HIV-1 and GP-36 for HIV-2 have been used for coating on nitro cellulose membrane and colloidal gold conjugate.
Oscar HCV test is intended used for qualitative detection of antibodies (IgG/IgM/IgA) to HCV (Hepatitis C virus) in human serum / plasma as in aid of HCV diagnosis. It is based upon lateral flow immuno assay and double antigen system has been used in the test formulation to have better sensitivity and specificity. Recombinant proteins of HCV (Core, NS3, NS4 and NS5) have been used for coating on nitro cellulose membrane and colloidal gold conjugate. Specimen of choice is serum / plasma and result can be obtained within 5-20 minutes. Oscar HCV test is available in 20T & 50T pack. It has shelf life of 24 months from date of manufacturing if stored at 2-30⁰ C under sealed conditions. The test has excellent sensitivity (100%) and specificity (99.8%).
Oscar Dengue antigen (NS-1) test is a rapid card test based upon lateral flow immuno assay for the qualitative detection of NS-1 antigen of Dengue virus in human serum / plasma as in aid of early diagnosis of dengue infection. The nitrocellulose membrane is immobilized with cocktail of monoclonal antibodies of dengue at test line position ‘T’ and goat anti rabbit IgG at control line position ‘C’. The colloidal gold is conjugated with monoclonal antibody of dengue and rabbit IgG. Oscar Dengue antigen (NS-1) test is available in multiple of 5T pack. Each pack contains individually pouched test device, sample dropper and product insert. NO buffer is required. Oscar Dengue antigen (NS-1) test has shelf life of 24 months from date of manufacturing if stored at 2-30⁰C in sealed condition.
Oscar Dengue Ab test is a rapid card test based upon lateral flow immuno assay for the qualitative detection of IgM and IgG antibodies to Dengue virus in human serum / plasma. The nitrocellulose membrane is immobilized with anti human IgG, anti human IgM and control line protein. The colloidal gold conjugate contains recombinant protein of Dengue. Oscar Dengue Ab test is available in multiple of 5T pack. Each pack contains individually pouched test devices, sample droppers, buffer vial and product insert. It has shelf life of 24 months from date of manufacturing if stored at 2-30⁰ C under sealed conditions.
Oscar Dengue Ag+ Ab test is a rapid card test based upon lateral flow immuno assay for the qualitative and differential detection of NS-1 antigen and IgM / IgG antibodies to Dengue virus in human serum / plasma. Test device has dual strip system. The test strip for NS-1 test contains monoclonal antibodies as test line protein and colloidal gold is conjugated with monoclonal antibody to dengue virus. The test strip of IgM/IgG test is immobilized with anti human IgG, anti human IgG and control line protein and colloidal gold conjugate contains recombinant protein of Dengue. Oscar Dengue Ag + Ab test is available in 10T pack. Each pack contains individually pouched test devices, sample droppers, buffer vial and product insert etc. It has shelf life of 24 months from date of manufacturing if stored at 2-30⁰ C under sealed conditions. Each kit is provided in 10 test pack.
Oscar Malaria Antigen ‘Pv/Pf’ card test is intended used for qualitative and differential detection of Pv (pLDH) and Pf (HRP-II) in human whole blood as in aid of rapid diagnosis of Malaria. It is based upon lateral flow immuno assay. Highly specific monoclonal antibodies specific to pLDH & HRP-II have been used for coating on nitro cellulose membrane and on colloidal gold conjugate in the test formulation to have better sensitivity and specificity for detection of Pv and Pf. Specimen of choice is freshly collected human whole blood and result can be obtained within 5-20 minutes.
Oscar HCG / Pregnancy card test is intended used for qualitative detection of HCG (Human chorionic gonadotropin) in human urine as in aid of early diagnosis pregnancy. It is based upon lateral flow immuno assay and highly specific monoclonal /polyclonal antibodies to HCG have been used for coating on nitro cellulose membrane and colloidal gold conjugate in the test formulation to have better sensitivity and specificity. Specimen of choice freshly collected urine and result can be obtained within 5-10 minutes. Oscar HCG card test is available in 40T pack and each kit contains individually pouched test cards, disposable droppers and product insert. It has shelf life of 24 months from date of manufacturing if stored at 2-30⁰ C under sealed conditions. The Oscar HCG test has excellent sensitivity and specificity with minimal detection limit of 25 mIU HCG/ml of urine.
Oscar HIV (4th Generation ELISA) detects antigen and antibody of HIV-1 & 2 in human serum / plasma. It is available in 96T pack.
Oscar HIV (3rd Generation ELISA) detects antibody of HIV-1 & 2 in human serum / plasma. It is available in 96T pack.
Oscar HCV ELISA detects antibody of HCV (Hepatitis C Virus) in human serum / plasma. It is available in 96T pack.
Oscar HBs Ag ELISA detects HBs Ag (Hepatitis B Surface antigen) in human serum / plasma. It is available in 96T pack.
Dengue NS-1 ELISA is intended used for qualitative detection of Dengue NS-1 antigen in human serum / plasma. It is available in 96T pack.
Oscar Syphilis ELISA is intended used for qualitative detection of antibodies of Treponema pallidum in human serum / plasma. Kit is available in 96T pack.
Randox is a global leader in healthcare diagnostics; today more than 5% of the world’s population – in excess of 370 million people across 145 countries – receives medical diagnosis using Randox products each year. Randox is the largest diagnostic company from the UK and exports over 95% of products worldwide. Our products and services are used in hospitals, clinical, research and molecular laboratories, food testing, forensic toxicology, life sciences, and veterinary laboratories. With more than 1400 employees of 44 nationalities, including 300 research scientists and engineers, we have offices and distribution in over 145 countries. There are four key manufacturing and research and development sites, located in County Antrim, Northern Ireland; Dungloe, County Donegal, Ireland; Bangalore, India; and in the Greater Washington DC area, USA. Our Randox Health Clinics are currently located in London, Liverpool, Belfast, amd Crumlin, with ambitious plans to roll out a number of new clinics across the world.
Patient care is the primary focus of clinical chemistry testing and Randox has developed the RX series of clinical chemistry analysers for high quality semi-automated and fully automated testing. The RX series continues to revolutionise a variety of laboratory types including:
We can provide dedicated diagnostic reagents for the Randox RX series, Hitachi™, AU™, Architect C™, Aeroset™ and Konelab™ range of chemistry analysers providing you with freedom of choice from an independent manufacturer. With flexible pack sizes and a comprehensive list of analyser applications available, you are sure to find what you are looking for. As always with Randox our diagnostic reagents are of the highest quality; this is recognised through official accreditation to both national and international standards including UKAS, ISO 13485:2003, and FDA. Benefits of Randox diagnostic reagents are:
Laboratory Quality Control is our passion and with more than 30 years’ experience developing Laboratory Quality Control for the in vitro diagnostics market we believe in producing high quality material designed to streamline procedures, whilst reducing costs in laboratories of all sizes and budgets. These qualities have been reflected in our Acusera true third party quality controls, Acusera 24.7 interlaboratory data management software and RIQAS EQA scheme.Randox is one of the largest manufacturers of true third party quality control solutions delivering reliable, high quality products designed to accurately assess instrument performance and ultimately provide confidence in patient test results. With more than 390 analytes available across the Acusera range and a wide range of formats providing flexibility & choice, we have a solution to suit you.
From its inception in 1990, RIQAS (Randox International Quality Assessment Scheme) has developed into one of the world’s largest global External Quality Assessment (EQA / Proficiency Testing (PT) schemes serving over 45,000 participants in more than 133 countries. Our main aim is to help clinical laboratories meet their quality requirements and most importantly, provide the best possible patient care.
Currently, a total of 33 comprehensive EQA programmes are available covering a wide range of clinical diagnostic testing. Our extensive programme menu is world renowned for reducing the number of individual EQA programmes required by even the most demanding laboratories. Effective consolidation in this way will not only deliver real cost savings but free up storage space and ultimately reduce the time spent preparing multiple samples at each EQA survey. Several flexible participation options are available allowing laboratories to customise the scheme to suit their unique requirements.
In 2012, RIQAS celebrated gaining accreditation to ISO/IEC 17043:2010. This standard outlines general requirements for proficiency testing and demonstrates our commitment to quality whilst providing both participants and accrediting bodies with confidence in the schemes operation.
PerkinElmer is a global leader committed to innovating for a healthier world. Our dedicated team of about 11,000 employees worldwide are passionate about providing customers with an unmatched experience as they help solve critical issues especially impacting the diagnostics, discovery and analytical solutions markets. Our innovative detection, imaging, informatics and service capabilities, combined with deep market knowledge and expertise, help customers gain earlier and more accurate insights to improve lives and the world around us.
Newborn screening is a form of preventive health care in which babies are tested within the first days of their life to discover evidence of diseases for which the principal symptoms may not yet be apparent.
In order for screening to be successful a simple and reliable test must exist. Also, there must be a treatment that makes a difference when the disease is detected early.
Accurately detect disorders in newborns earlier and more efficiently with our market-leading neonatal screening products. We offer laboratories complete systems of high-quality, validated products, including newborn screening kits, consumables, instruments and software.
Biotinidase deficiency is an autosomal recessive metabolic disorder in which biotin is not released from proteins in the diet during digestion or from normal protein turnover in the cell. This situation results in biotin deficiency. Biotin, also called vitamin B7, is an important water-soluble nutrient that aids in the metabolism of fats, carbohydrates, and proteins. Biotin deficiency can result in behavioral disorders, lack of coordination, learning disabilities and seizures. Biotin supplementation can alleviate and sometimes totally stop such symptoms.
Biotinidase deficiency is treated with oral biotin supplementation, which prevents development of the clinical symptoms.
Because the diagnosis and therapy of metabolic disorders is complex, the pediatrician is advised to manage the patient in close collaboration with a consulting pediatric metabolic disease specialist. It is recommended that parents travel with a letter of treatment guidelines from the patient’s physician.
The deficiency of thyroid hormones in the neonate has been known since antiquity. Most cases prior to the 20th century were caused by iodine deficiency. Though still a prevalent nutritional disease worldwide, iodine deficiency rarely causes congenital hypothyroidism (CH) in western countries.
In greater than 95% of newborn infants with CH, there are no symptoms or signs of CH when the diagnosis is suspected by newborn screening. During the first 2 to 6 months of life, an affected, untreated infant with moderate to severe hypothyroidism may have persistent hyperbilirubinemia, edema, an umbilical hernia, enlarged fontanelles, and an absent, hypoplastic, normal or enlarged thyroid gland; then gradually develops lethargy, poor feeding, macroglossia, hypothermia, constipation, dry and sallow skin, hoarse cry, circumoral pallor, and mottling of the skin.
Treatment of hypothyroidism is relatively uncomplicated. As soon as tests to confirm the diagnosis of CH are obtained, levothyroxine (L-thyroxine) should be started promptly. Central CH may require additional management based on associated findings. Evaluation and monitoring should be performed in conjunction with a pediatric endocrine specialist.
Individuals intolerant to ingested galactose were described as early as 1908, but it wasn’t until 1935 that elimination of galactose from the diet was shown to reverse the acute toxicity syndrome associated with galactosemia. The Leloir pathway, the main pathway of galactose metabolism, was elucidated in the early 1950s. In 1955, the accumulation of galactose-1-phosphate in red blood cells of infants with impaired galactose metabolism was demonstrated.GALT deficiency most often presents as a life threatening illness within the first two weeks after birth. Poor feeding, poor weight gain, vomiting and diarrhea, lethargy, and hypotonia are initial symptoms. On physical examination, infants are jaundiced with hepatomegaly, may have a full fontanelle and show prolonged bleeding after venous or arterial sampling.
Immediate exclusion of dietary galactose (breast feeding, cow’s milk) should be instituted at the first suspicion of galactosemia. Infant soy formulas are recommended unless there is significant liver disease. For the newborn who is seriously ill at the time of diagnosis, supportive care may include treatment with vitamin K and fresh-frozen plasma to correct clotting abnormalities. Gram-negative sepsis should be assumed and appropriate IV antibiotics given.
The deficiency in one of the five enzymes required in the steroidogenic pathway for the biosynthesis of cortisol (hydrocortisone) results in a group of diseases known collectively as congenital adrenal hyperplasia (CAH).The diseases are inherited as autosomal recessive disorders. As a result of impaired cortisol synthesis by the adrenal cortex, there is excessive secretion from the pituitary of adrenocorticotropic hormone (ACTH), or corticotrophin, which stimulates the adrenal cortex to synthesize and secrete more cortisol. ACTH stimulation causes diffuse hyperplasia of the adrenal gland, and usually the disease is recognized in infancy.
Oral hydrocortisone in a physiologic replacement dose is the treatment of choice for CAH. The more potent glucocorticoids are contraindicated in the growing child and adolescent because of the difficulty in determining a physiologic versus pharmacologic dose. In children with salt-losing CAH, 9·-fluorohydrocortisone should maintain normal electrolyte balance without excessive natriuretic or glucocorticoid effects. Monitoring plasma 17-OHP and androgen levels, growth velocity, and an occasional bone age offer the basic tools for adequate, effective therapy.
Sickle cell disease was the first hemoglobinopathy to be linked to an inherited structural defect in the beta globin gene, and the first in which the point mutation resulting in the defect was identified and characterized. The scope of newborn screening for sickle cell disease, which began over 30 years ago, has evolved to include other hemoglobin diseases.
In the newborn period, a transition occurs from primarily fetal hemoglobin (HbF) production to adult hemoglobin (HbA). This transition temporarily masks symptoms of disease. As a result, diseases associated with red blood cell sickling (Hb S, C, S/C, S/O, and S/D diseases) usually present during the first or second year of life, although milder cases may present much later. Usual presenting features are failure to thrive, repeated infection in infancy, painful dactylitis, and pallor. At this stage typical hematologic findings are established.
Apart from bone marrow transplantation, there is no curative treatment for hemoglobin disorders. Management for newborns affected with sickling diseases typically involves oral penicillin given daily and maintained throughout childhood, and vaccination against Pneumococcus, Meningococcus, and H. influenzae.
Cystic fibrosis (CF) was first recognized as a clinical entity in 1938. Its genetic nature and autosomal recessive inheritance pattern were described in 1946. In 1948, patients with CF were observed to lose excess salt in their sweat which led to development of the chloride sweat test (a diagnostic test still in use). More than 1,600 mutations within the CFTR gene have been identified, and while some mutations are often associated with severe sequelae, even siblings with identical CF mutations may have dramatically different clinical courses. CF may affect the lung and upper respiratory tract, GI tract, pancreas, liver, sweat glands, and genitourinary tract. Nutritional abnormalities secondary to pancreatic insufficiency also have predictable consequences for growth and development.
Early diagnosis by newborn screening has allowed earlier combined anti-inflammatory and antibiotic therapies to combat upper respiratory infections and nutritional supplementation to avoid nutritional deficits. Dramatic progress has been made in improving quality of life for these newborns.
Phenylketonuria (PKU) is a disorder of amino acid metabolism that was recognized as a genetic defect as early as 1930. Phenylalanine is an essential amino acid that is converted to tyrosine by action of the enzyme phenylalanine hydroxylase. A block in this reaction due to deficient activity of phenylalanine hydroxylase causes PKU and results in severe central nervous system symptoms. Phenylalanine hydroxylase requires tetrahydrobiopterin as a cofactor and its deficiency, caused by an enzyme defect in the synthesis or recycling of tetrahydrobiopterin, can also result in PKU.
PKU babies typically appear normal at birth and in the neonatal period. Infants may later exhibit irritability, posturing, increased deep tendon reflexes, a peculiar “mousy” odor, and vomiting. Pale pigmentation develops in hair and skin, and seizures are sometimes present. Phenylalanine accumulates within the first days of life and tyrosine levels tend to be low.
Patients with PKU need to maintain normal, physiological levels of phenylalanine and tyrosine for life. Studies have shown that periods of elevated Phenylalanine affect brain development and function. Newborns diagnosed with PKU should begin dietary treatment as soon as possible. Several commercial PKU formulas and various phenylalanine-restricted foods are available. Phenylalanine (and tyrosine) should be measured on a regular basis to follow dietary control.
Glucose-6-phosphate dehydrogenase (G6PD) functions throughout the body, but its deficiency is seen predominantly in its effects on the red blood cells. G6PD anchors the production of NADPH and glutathione to protect the body from oxidative insults. Erythrocytes are especially sensitive to oxidative damage. G6PD deficiency can result in neonatal jaundice and in life threatening reactions to several medications, foods and infections.
Infants with G6PD deficiency may be at increased risk for pathological newborn jaundice and may warrant close monitoring for associated complications during the newborn period. Otherwise, treatment of G6PD deficiency is avoidance. For the infant, this means avoidance of several medications routinely prescribed for infections and illness. Strict attention to the ingredients of prepared foods and restaurant meals is required as fava beans are a frequent addition to prepared foodstuffs. Patients should not be exposed to moth balls containing naphthalene. The adverse affects of infection on patients with G6PD Deficiency can be acute and life threatening. Over exertion from exercise and work leading to dehydration and hypoglycemia can precipitate clinical symptoms. As mentioned above, patients mindful of these limitations can lead a normal life of exercise and choice of vocation.
PerkinElmer is a global company focused on improving the health and safety of people and their environment. Within the field of fetal and maternal healthcare, PerkinElmer offers complete screening solutions including instrumentation, reagents and risk calculation software for early detection of pregnancy related anomalies. Three different platforms; DELFIA®, DELFIA® Xpress and AutoDELFIA®, offer you optimal throughput for your specific needs for fetal and maternal screening. PerkinElmer’s complete solution enables pre-eclampsia risk assessment in all trimesters of pregnancy and provides a complete set of markers needed for Downs syndrome screening in both 1st and 2nd trimesters of pregnancy. Read more about pre-eclampsia screening here. PerkinElmer has recently acquired Vanadis Diagnostics, which is developing a novel non-sequencing, non-PCR based solution for cfDNA analysis. In the future this acquisition will able PerkinElmer to offer a simplified, cost-effective, high-throughput screening test to help facilitate wider access to non-invasive prenatal testing for pregnant women. Maternal fetal products availability and claims may differ from country to county based on regulations and product approvals. Please check availability with your local distributor.
Assess the risk of fetal chromosomal abnormalities using fewer invasive procedures. We offer screening systems for aneuploidies that combine markers and assays for high detection rates with low numbers of false positives. Such screening early in pregnancy allows expectant parents to make timely medical management decisions. Our first and second trimester prenatal screening assays support both laboratories and clinics, with automated platforms available for AutoDELFIA® and DELFIA Xpress®. Victor2 D™ together with DELFIA® kits allow measurement of assays using semi-automated means. Our safe, non-invasive first trimester screening tests are based on biochemical markers from maternal serum and provide expectant parents with a risk assessment for trisomy 21, 13, and 18.
Predict pre-eclampsia earlier through improved biomarkers. Our PlGF (Placental Growth Factor) assay was the first developed commercially for first trimester screening. It measures free PlGF (isoform 1). Used in combination with biophysical markers and established risk factors, it is particularly effective for detecting preterm pre-eclampsia before 13 weeks gestation. As additional safeguards for patients at later stages of pregnancy, the PlGF assay can also be used as part of the same combination of markers in the second and third trimesters. PerkinElmer biochemistry assays and measuring instruments are complemented by essential items such as native controls to ensure the integrity of results. We also supply dedicated pre-eclampsia screening software for critical first trimester risk calculations. Together, these products constitute a complete, practical solution for pre-eclampsia prediction.